Head-to-head · free
AbCellera Biologics Inc. vs Akanda Corp.
ABCL vs AKAN — return on capital, cash generation, margins and balance sheet side by side.
ABCL
1 / 2
measures where ABCL leads
AKAN
1 / 2
measures where AKAN leads
A simple count of which company scores better on each measure — not a recommendation to buy or sell.
| Measure | ABCL · FY2025 | AKAN |
|---|---|---|
| Revenue | $75.1M | — |
| Net income | (146.4M) | — |
| Revenue growth (yearly, multi-year) | -33.1% | — |
| Free cash flow | (174.1M) | — |
| Free cash flow margin | -231.7% | — |
| Net cash / (debt) | — | — |
| ROIC | — | — |
| Return on equity | -14.5% | — |
| Gross margin | — | -60.5% |
| Operating margin | -270.5% | -1931.0% |
| Net debt / EBITDA | 0.68x | -2.93x |
Figures are as reported by each company; latest fiscal year shown.
Where AbCellera Biologics Inc.'s cash went (FY2025)
- Capital spending
- $42.8M
- Buybacks
- —
- Dividends
- —
- Acquisitions
- —
- Net debt issued / (repaid)
- —
Ask which business is stronger
"Which one reinvests at higher returns?" "Who carries more risk in its filings?" Get answers drawn straight from both companies' filings.
Compare them free